Home » Stocks » BCEL

Atreca, Inc. (BCEL)

Stock Price: $9.58 USD 0.67 (7.52%)
Updated May 14, 2021 4:00 PM EDT - Market closed
Market Cap 353.42M
Revenue (ttm) n/a
Net Income (ttm) -91.69M
Shares Out 36.84M
EPS (ttm) -6.36
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $9.58
Previous Close $8.91
Change ($) 0.67
Change (%) 7.52%
Day's Open 9.05
Day's Range 9.05 - 9.70
Day's Volume 308,024
52-Week Range 8.87 - 25.03

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

REDWOOD CITY, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platf...

1 month ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a ...

2 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a u...

2 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a u...

2 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a u...

6 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery...

6 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a u...

7 months ago - GlobeNewsWire

Atreca, Inc. (BCEL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

7 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discov...

8 months ago - GlobeNewsWire

Atreca, Inc. (BCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

8 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a...

9 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a...

9 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., July 16, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Nasdaq: BCEL), a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-bas...

10 months ago - GlobeNewsWire

REDWOOD CITY, Calif., July 15, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Nasdaq: BCEL), a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immu...

10 months ago - GlobeNewsWire

Atreca, Inc. (BCEL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

10 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif. and MONROVIA, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutic...

10 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., June 11, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a...

11 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discover...

11 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., May 14, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a ...

1 year ago - GlobeNewsWire

These three clinical-stage biotechs are all bargains after last month's marketwide downturn.

Other stocks mentioned: ADAP, CRSP
1 year ago - The Motley Fool

The coronavirus induced sell-off has created a number of attractive buying opportunities.

Other stocks mentioned: ABBV, AGEN, APHA, BCYC, BMY, CPRX, CRNX ...
1 year ago - The Motley Fool

These relative newcomers to the landscape of publicly-traded biotech stocks could be big winners for early shareholders.

Other stocks mentioned: CRNX
1 year ago - The Motley Fool

SOUTH SAN FRANCISCO, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discove...

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on the development of novel cancer therapeutics generated through a...

1 year ago - GlobeNewsWire

Atreca's FDA Clearance Of Phase 1 Study Using ATRC-101 Brings It Into Unchartered Territory

1 year ago - Seeking Alpha

First IND clearance of a clinical candidate derived from Atreca’s differentiated drug discovery platform

1 year ago - GlobeNewsWire

REDWOOD CITY, Calif., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the huma...

1 year ago - GlobeNewsWire

The oncology drug development space holds “tremendous scarcity value for novel targets," and Atreca Inc’s (NASDAQ: BCEL) stock offers an investment opportunity at an attractive valuation, according to S...

1 year ago - Benzinga

Atreca, Inc. shares opened for trade Thursday morning at $19.90. The IPO of 7.35 million shares was priced at $17.

1 year ago - Benzinga

About BCEL

Atreca, Inc., a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It has a collaboration and license agreement with Xencor, Inc. fo... [Read more...]

Industry
Biotechnology
IPO Date
Jun 20, 2019
CEO
John Orwin
Employees
130
Stock Exchange
NASDAQ
Ticker Symbol
BCEL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for Atreca stock is "Strong Buy." The 12-month stock price forecast is 30.22, which is an increase of 215.45% from the latest price.

Price Target
$30.22
(215.45% upside)
Analyst Consensus: Strong Buy